Papers
4
Total Citations
111
H-Index
3
About
Dr. Chuangui Chen is a leading surgical oncologist whose research centers on the multimodal treatment of esophageal squamous cell carcinoma (ESCC), with a particular focus on advancing minimally invasive surgical techniques and neoadjuvant immunotherapy. His most impactful work includes the Keystone-001 trial protocol, which investigates the safety and effectiveness of combining pembrolizumab with paclitaxel and cisplatin as neoadjuvant therapy for stage III ESCC—a study that has garnered 62 citations and addresses a critical need in a disease with high incidence in China. Dr. Chen has also made seminal contributions to the refinement of robot-assisted McKeown esophagectomy, specifically in the challenging area of lymph node dissection around the left recurrent laryngeal nerve. His comparative study of robot-assisted versus video-assisted techniques (38 citations) and his analysis of the learning curve for this procedure across 417 patients provide essential guidance for surgical training and quality improvement. By demonstrating that induction therapy does not compromise the safety or efficacy of robotic surgery, Dr. Chen has helped solidify the role of robotic platforms in complex esophageal cancer care. His work is pivotal in shaping evidence-based, personalized surgical strategies for ESCC patients.
Research Focus
Key Achievements
Top Papers
- 1
- 2
- 3
- 4